Last updated: February 19, 2026
Eurasian Patent EA200800784, granted to Pharmasset Inc. on December 29, 2008, protects a method for treating or preventing hepatitis C virus (HCV) infection. The patent's claims are centered on the use of specific interferon-alpha variants in combination with ribavirin. The patent landscape surrounding this invention is characterized by a high degree of activity in HCV therapeutics, with numerous companies holding patents on various antiviral agents, delivery methods, and combination therapies.
What Does Eurasian Patent EA200800784 Claim?
The core of Eurasian Patent EA200800784 lies in its method claims. Specifically, the patent claims:
- A method of treating or preventing a hepatitis C virus (HCV) infection in a human subject, comprising administering to the subject an effective amount of interferon-alpha in combination with ribavirin. [1]
The patent further elaborates on specific aspects of this combination therapy:
- Interferon-alpha variants: The patent does not exclusively limit itself to naturally occurring interferon-alpha but encompasses variants. This broadens the scope to include engineered or modified forms of interferon-alpha that retain therapeutic activity.
- Dosage and administration: While specific dosages are not detailed in the primary claims, the patent implies that the administered amounts must be "effective," meaning sufficient to achieve a therapeutic outcome. The method of administration is not restricted, allowing for various routes and schedules.
- Combination therapy: The essential element is the concurrent or sequential administration of interferon-alpha and ribavirin. This combination was a cornerstone of early direct-acting antiviral (DAA) therapy for HCV.
What is the Geographical Scope of EA200800784?
The Eurasian Patent Organization (EAPO) operates as a regional patent system. A single patent granted by the EAPO has effect in all designated member states of the Eurasian Patent Convention that the applicant chooses to validate the patent in. As of the grant date of EA200800784, the member states of the EAPO include:
- Armenia
- Azerbaijan
- Belarus
- Kazakhstan
- Kyrgyzstan
- Moldova
- Russian Federation
- Tajikistan
- Turkmenistan
Therefore, the patent's geographical coverage extends to these nine countries, providing exclusive rights for the claimed method within their respective territories.
What Was the Technological Context at the Time of Filing?
Eurasian Patent EA200800784 was filed against a backdrop of significant advancements in HCV treatment. Prior to the advent of highly effective DAAs, the standard of care for chronic HCV infection primarily involved interferon-based therapies.
- Interferon-alpha: This cytokine was one of the first approved antiviral agents for HCV. It functions by stimulating the host immune system to fight the virus. However, its efficacy was limited, and it was associated with significant side effects, including flu-like symptoms, depression, and hematological abnormalities.
- Ribavirin: This synthetic nucleoside analog was found to have broad-spectrum antiviral activity. When combined with interferon-alpha, ribavirin significantly improved sustained virologic response (SVR) rates compared to interferon monotherapy. The combination was the standard of care for over a decade.
- HCV infection: HCV is a blood-borne virus that primarily affects the liver, leading to chronic inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma. The development of effective treatments was a major public health priority.
The filing of EA200800784 in the late 2000s reflects the ongoing efforts to optimize and patent existing treatment paradigms before the disruptive introduction of DAAs in the early 2010s.
What is the Competitive Landscape for HCV Therapeutics?
The patent landscape for HCV therapeutics is highly competitive and has evolved rapidly. Companies like Gilead Sciences, AbbVie, Bristol Myers Squibb, and Merck have invested heavily in developing novel antiviral agents.
Key areas of patenting activity include:
- Direct-Acting Antivirals (DAAs): These drugs directly target specific viral proteins essential for replication. This class of drugs revolutionized HCV treatment by offering higher efficacy and better tolerability than interferon-based regimens. Patents in this area cover NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors.
- Combination Therapies: Patents often claim specific combinations of DAAs, or combinations of DAAs with other antiviral agents, to achieve synergistic effects and overcome resistance.
- Resistance Mutations: As treatments evolved, so did the emergence of viral resistance. Patents have been filed for compounds effective against specific resistance mutations.
- Formulations and Delivery Methods: Innovations in drug delivery, such as long-acting injectables or improved oral formulations, are also subjects of patent protection.
- HCV Genotypes: Different HCV genotypes exhibit varying responses to treatment. Patents may specify treatments effective against particular genotypes or pan-genotypic regimens.
Given that EA200800784 claims a method involving interferon-alpha and ribavirin, its primary competitive context lies within the era of interferon-based treatment. However, it's important to consider its relevance in the broader HCV patent landscape.
Comparative Patent Analysis: EA200800784 vs. Later HCV Patents
To understand the positioning of EA200800784, a comparative analysis with patents covering DAAs is instructive.
| Patent/Technology |
Primary Mechanism |
Key Companies Involved |
Era of Dominance |
| EA200800784 |
Interferon-alpha and Ribavirin Combination |
Pharmasset Inc. (later acquired by Gilead) |
Pre-DAA era (prior to early 2010s) |
| Gilead Sciences Patents (e.g., US8697679) |
NS5A inhibitors (e.g., Ledipasvir), NS5B inhibitors |
Gilead Sciences |
DAA era (early 2010s onwards) |
| AbbVie Patents (e.g., US8993045) |
NS3/4A protease inhibitors (e.g., Paritaprevir), NS5A inhibitors (e.g., Ombitasvir) |
AbbVie |
DAA era (early 2010s onwards) |
| Bristol Myers Squibb Patents (e.g., US8476239) |
NS5A inhibitors (e.g., Daclatasvir) |
Bristol Myers Squibb |
DAA era (early 2010s onwards) |
Eurasian Patent EA200800784 represents an older generation of HCV treatment. While it was likely highly relevant during its period of enforceability, the advent of DAAs has largely superseded interferon-based therapies for chronic HCV due to significantly higher cure rates and improved safety profiles.
What is the Status and Enforcement History of EA200800784?
Information on the specific enforcement history or litigations directly involving Eurasian Patent EA200800784 is not publicly detailed in standard patent databases. However, the general patent prosecution and grant process in the EAPO system provides insight:
- Grant Date: December 29, 2008.
- Term: Patents granted by the EAPO typically have a term of 20 years from the filing date. The filing date for EA200800784 would determine its expiry. Assuming a typical filing date prior to grant, the patent's term likely expired or is nearing expiry, especially considering the grant date.
- Validation: For the patent to be in force in specific member states, it must have been validated and annual renewal fees paid. The absence of such information suggests potential lapsing due to non-payment of fees or the patent's natural expiry.
- Acquisition by Gilead: Pharmasset Inc., the original assignee, was acquired by Gilead Sciences in 2011 for approximately $11 billion. This acquisition was primarily for Gilead's then-pipeline HCV DAAs, such as sofosbuvir. While the interferon-based patents may not have been the primary focus of this acquisition, they would have transferred with the company.
The competitive landscape shift towards DAAs likely reduced the commercial incentive to vigorously defend older interferon-based patents like EA200800784. Enforcement would depend on active commercial activity in the designated EAPO countries utilizing the specific claimed method and the patent's remaining term.
How Does EA200800784 Interact with the Broader Patent Landscape?
Eurasian Patent EA200800784 falls into the category of method-of-treatment patents. In the context of the broader HCV therapeutic landscape, it represents foundational intellectual property for a combination therapy that was once the standard of care.
Its interaction with later patents can be understood in several ways:
- Prior Art: Patents like EA200800784 serve as prior art for subsequent patent applications. Inventors seeking to patent new HCV treatments must demonstrate novelty and inventive step over existing patented methods, including those involving interferon and ribavirin.
- Freedom to Operate (FTO): Companies developing new HCV therapies would have needed to conduct FTO analyses to ensure their products did not infringe existing patents. While DAAs largely obviated the need to consider interferon/ribavirin patents for new drug development, historical FTO assessments would have included such claims.
- Patent Expiry and Generic Competition: As patents like EA200800784 approach or reach expiry, they open avenues for generic manufacturers to produce and market the claimed treatments. However, the commercial viability of generic interferon/ribavirin therapies in EAPO countries would be influenced by the availability and cost-effectiveness of newer DAA-based treatments.
The patent landscape for HCV is a dynamic ecosystem where earlier foundational patents establish a baseline, and later innovations build upon or circumvent prior art. EA200800784 is situated at the earlier end of this spectrum, marking a significant step in the evolution of HCV therapy.
Key Takeaways
- Eurasian Patent EA200800784 claims a method for treating or preventing HCV infection using a combination of interferon-alpha and ribavirin.
- The patent's geographical scope covers nine member states of the Eurasian Patent Organization, including Russia and Kazakhstan.
- Granted in December 2008, the patent reflects the standard of care for HCV before the widespread adoption of direct-acting antivirals (DAAs).
- The patent landscape for HCV therapeutics is highly competitive, with subsequent innovations focusing on more effective and safer DAA-based regimens.
- While specific enforcement data is limited, the patent's term is approaching expiry, and its commercial relevance has diminished due to the therapeutic superiority of DAAs.
Frequently Asked Questions
-
What is the expiration date of Eurasian Patent EA200800784?
The expiration date is determined by the patent's filing date plus a 20-year term. Without the specific filing date, a precise expiration date cannot be provided, but given the grant date of December 29, 2008, the patent is likely expired or very near expiry.
-
Can generic versions of interferon-alpha and ribavirin therapy be marketed in EAPO member states if EA200800784 is still in force?
If the patent is still in force in a specific EAPO member state and the therapy falls within its claims, generic marketing would constitute infringement. However, the therapeutic landscape has shifted significantly towards DAAs, potentially limiting the commercial interest in generic interferon/ribavirin.
-
Does EA200800784 cover specific interferon-alpha variants or only the natural form?
The patent's claims encompass interferon-alpha, which generally includes both natural and engineered variants that retain therapeutic activity, broadening its scope beyond the wild-type protein.
-
Was this patent acquired by Gilead Sciences?
Yes, Pharmasset Inc., the original assignee, was acquired by Gilead Sciences in 2011.
-
What is the current therapeutic significance of the treatment claimed in EA200800784 in major pharmaceutical markets?
The combination of interferon-alpha and ribavirin is no longer considered a first-line treatment for chronic HCV in major pharmaceutical markets due to the development of direct-acting antivirals that offer higher cure rates and improved tolerability.
Citations
[1] Eurasian Patent Organization. (2008). Eurasian Patent EA200800784.
